Baseline Serum Concentrations of TRAIL in Early Rheumatoid Arthritis: Relationship with Response to Disease-modifying Antirheumatic Drugs
Authors:
- Paola SecchieroPaola Secchiero
- Federica CoralliniFCFederica Corallini
- Gabriella CastellinoGCGabriella Castellino
- Alessandra BortoluzziABAlessandra Bortoluzzi
- Lorenzo CarusoLCLorenzo Caruso
- Serena BugattiSBSerena Bugatti
- Raffaella BoscoRBRaffaella Bosco
- Maurizio MontecuccoMMMaurizio Montecucco
- Francesco TrottaFTFrancesco Trotta
- 15 May 2010
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 37 (7) , 1461-1466
Abstract
Objective. To assess the relationship between serum concentrations of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and osteoprotegerin (OPG) and the therapeutic response to disease-modifying antirheumatic drugs (DMARD) in patients with early rheumatoid arthritis (RA). Methods. Circulating levels of TRAIL and its soluble receptor OPG were measured by ELISA in paired serum samples obtained from 66 patients with early RA at their first visit (baseline) and after 1 year of therapy. Levels of TRAIL and OPG were analyzed in relation to the clinical response, defined by the 28-joint count Disease Activity Score (DAS28). Results. Both serum TRAIL and OPG increased after DMARD therapy. Baseline levels of TRAIL, but not OPG, were significantly higher (p < 0.05) in the patients that achieved a clinical response by DAS28 after 1 year of therapy, versus patients without clinical response to DMARD. Baseline serum levels of TRAIL were higher (p < 0.01) in rheumatoid factor-negative patients. Conclusion. Our data suggest that the basal level of circulating TRAIL is an important determinant in the therapeutic response to DMARD in patients with early RA.Keywords
This publication has 33 references indexed in Scilit:
- The course of established rheumatoid arthritisBest Practice & Research Clinical Rheumatology, 2007
- Investigating the Interaction between Osteoprotegerin and Receptor Activator of NF-κB or Tumor Necrosis Factor-related Apoptosis-inducing LigandJournal of Biological Chemistry, 2007
- The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biologyCytokine & Growth Factor Reviews, 2006
- Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Induces Rheumatoid Arthritis Synovial Fibroblast Proliferation through Mitogen-activated Protein Kinases and Phosphatidylinositol 3-Kinase/AktJournal of Biological Chemistry, 2005
- Intra-articular injection of recombinant TRAIL induces synovial apoptosis and reduces inflammation in a rabbit knee model of arthritisArthritis Research & Therapy, 2005
- Rheumatoid arthritis synovial fluid fibroblasts express TRAIL‐R2 (DR5) that is functionally activeArthritis & Rheumatism, 2004
- Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cellsClinical and Experimental Immunology, 2004
- CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritisJournal of Clinical Investigation, 2003
- TRAIL-R2 (DR5) Mediates Apoptosis of Synovial Fibroblasts in Rheumatoid ArthritisThe Journal of Immunology, 2003
- Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Is an Inhibitor of Autoimmune Inflammation and Cell Cycle ProgressionJournal of Experimental Medicine, 2000